MINI FUTURE LONG - MODERNA | Market Closed - Deutsche Boerse AG 20:50:26 25/06/2024 BST | ||
| 7.46 EUR | +0.27% |
|
| Current month | -6.16% | ||
| 1 month | -26.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 7.46 | +0.27% |
| 24/06/24 | 7.44 | +3.33% |
| 21/06/24 | 7.2 | -0.69% |
| 20/06/24 | 7.25 | +4.47% |
| 19/06/24 | 6.94 | -3.21% |
Delayed Quote Deutsche Boerse AG
Last update June 25, 2024 at 08:50 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PN0QRZ |
| ISIN | DE000PN0QRZ2 |
| Date issued | 28/05/2020 |
| Strike | 57.33 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 39.18 € |
|---|---|
| Lowest since issue | 0.81 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
137.6
USD
Average target price
145.9
USD
Spread / Average Target
+6.00%
- Stock Market
- Certificates
- Certificat
